WO2026120069 - HUMANIZED ANTI-PACAP ANTIBODY AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2026/120069
Publication Date
11.06.2026
International Application No.
PCT/EP2025/085473
International Filing Date
04.12.2025
Title **
[English]
HUMANIZED ANTI-PACAP ANTIBODY AND USES THEREOF
[French]
ANTICORPS ANTI-PACAP HUMANISÉ ET SES UTILISATIONS
Applicants **
H. LUNDBECK A/S
Inventors
ABDUR-RASHEED ASUNI, Ayodeji
AREBERG, Johan
RODE, Frederik
Priority Data
24217681.6
05.12.2024
EP
25187137.2
03.07.2025
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2364 | |
| EPO | Filing, Examination, Granting | 10473 | |
| Japan | Filing, Examination, Granting | 2265 | |
| South Korea | Filing, Examination, Granting | 2254 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,096
Contact Us
Abstract[English]
The present invention is directed to an antibody having binding specificity for PACAP for the treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.[French]
La présente invention concerne un anticorps ayant une spécificité de liaison pour PACAP pour le traitement de maladies et de troubles associés à PACAP et des affections où l'antagonisme des activités liées au PACAP, telles que la vasodilatation, la photophobie, la dégranulation des mastocytes et/ou l'activation neuronale, serait thérapeutiquement bénéfique.